The major product from
drug metabolism of trimebutine in human beings is
nortrimebutine,[2] which comes from removal of one of the methyl groups attached to the nitrogen atom. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the
migrating motor complex in the digestive tract.[3]
Both trimebutine and its metabolite[citation needed] are commercially available.
Brand names
The
maleic acid salt of trimebutine is marketed under the
trademarks of Antinime, Cineprac, Colospasmyl, Colypan, Crolipsa, Debricol, Debridat, Digedrat, Espabion, Gast Reg, Irritratil, Krisxon, Muttifen, Neotina, Polybutin,[4] Sangalina, Trebutel, Tribudat, Tributina, Trim, Trimeb, Trimedat, and Trimedine.
^Roman FJ, Lanet S, Hamon J, Brunelle G, Maurin A, Champeroux P, et al. (June 1999). "Pharmacological properties of trimebutine and N-monodesmethyltrimebutine". The Journal of Pharmacology and Experimental Therapeutics. 289 (3): 1391–7.
PMID10336531.
^Jhee OH, Lee YS, Shaw LM, Jeon YC, Lee MH, Lee SH, Kang JS (January 2007). "Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC-MS/MS method". Clinica Chimica Acta; International Journal of Clinical Chemistry. 375 (1–2): 69–75.
doi:
10.1016/j.cca.2006.06.006.
PMID16854404.
The major product from
drug metabolism of trimebutine in human beings is
nortrimebutine,[2] which comes from removal of one of the methyl groups attached to the nitrogen atom. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the
migrating motor complex in the digestive tract.[3]
Both trimebutine and its metabolite[citation needed] are commercially available.
Brand names
The
maleic acid salt of trimebutine is marketed under the
trademarks of Antinime, Cineprac, Colospasmyl, Colypan, Crolipsa, Debricol, Debridat, Digedrat, Espabion, Gast Reg, Irritratil, Krisxon, Muttifen, Neotina, Polybutin,[4] Sangalina, Trebutel, Tribudat, Tributina, Trim, Trimeb, Trimedat, and Trimedine.
^Roman FJ, Lanet S, Hamon J, Brunelle G, Maurin A, Champeroux P, et al. (June 1999). "Pharmacological properties of trimebutine and N-monodesmethyltrimebutine". The Journal of Pharmacology and Experimental Therapeutics. 289 (3): 1391–7.
PMID10336531.
^Jhee OH, Lee YS, Shaw LM, Jeon YC, Lee MH, Lee SH, Kang JS (January 2007). "Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC-MS/MS method". Clinica Chimica Acta; International Journal of Clinical Chemistry. 375 (1–2): 69–75.
doi:
10.1016/j.cca.2006.06.006.
PMID16854404.